

Vincent Ravery

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/569368/publications.pdf>

Version: 2024-02-01

48
papers

2,492
citations

218592

26
h-index

223716

46
g-index

55
all docs

55
docs citations

55
times ranked

2190
citing authors

#	ARTICLE	IF	CITATIONS
1	PROSPECTIVE EVALUATION OF PROSTATE CANCER DETECTED ON BIOPSIES 1, 2, 3 AND 4: WHEN SHOULD WE STOP?. Journal of Urology, 2001, 166, 1679-1683.	0.2	392
2	Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology, 2002, 60, 4-9.	0.5	215
3	EXTENSIVE BIOPSY PROTOCOL IMPROVES THE DETECTION RATE OF PROSTATE CANCER. Journal of Urology, 2000, 164, 393-396.	0.2	150
4	A 970 Hounsfield units (HU) threshold of kidney stone density on non-contrast computed tomography (NCCT) improves patients' selection for extracorporeal shockwave lithotripsy (ESWL): evidence from a prospective study. BJU International, 2012, 110, E438-42.	1.3	134
5	Preoperative imaging in renal cell cancer. World Journal of Urology, 2004, 22, 307-315.	1.2	119
6	Comparison of the BTA <i>stat</i> ™ Test with Voided Urine Cytology and Bladder Wash Cytology in the Diagnosis and Monitoring of Bladder Cancer. European Urology, 1999, 35, 52-56.	0.9	113
7	Pathological features of prostate cancer detected on initial and repeat prostate biopsy: Results of the prospective European prostate cancer detection study. Prostate, 2001, 47, 111-117.	1.2	88
8	Frequency of renal phosphate leak among patients with calcium nephrolithiasis. Kidney International, 2001, 60, 272-276.	2.6	84
9	PAIN AND MORBIDITY OF AN EXTENSIVE PROSTATE 10-BIOPSY PROTOCOL: A PROSPECTIVE STUDY IN 289 PATIENTS. Journal of Urology, 2002, 167, 218-221.	0.2	83
10	RADICAL PROSTATECTOMY FOR PROSTATE CANCER: THE PERINEAL APPROACH INCREASES THE RISK OF SURGICALLY INDUCED POSITIVE MARGINS AND CAPSULAR INCISIONS. Journal of Urology, 1998, 160, 1383-1385.	0.2	77
11	PSA Progression Following Radical Prostatectomy and Radiation Therapy: New Standards in the New Millennium. European Urology, 2003, 43, 12-27.	0.9	73
12	An artificial neural network to predict the outcome of repeat prostate biopsies. Urology, 2003, 62, 456-460.	0.5	69
13	Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma?. , 1996, 78, 1079-1084.		66
14	Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. BMC Cancer, 2016, 16, 704.	1.1	60
15	Absence of microsatellite instability in transitional cell carcinoma of the bladder. Urology, 2000, 55, 287-291.	0.5	48
16	Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 93-101.	0.8	47
17	Can Power Doppler Enhanced Transrectal Ultrasound Guided Biopsy Improve Prostate Cancer Detection on First and Repeat Prostate Biopsy?. European Urology, 2004, 46, 451-456.	0.9	46
18	Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy. Urology, 2002, 59, 409-413.	0.5	45

#	ARTICLE	IF	CITATIONS
19	Is There a Role for Bladder Preserving Strategies in the Treatment of Muscle-Invasive Bladder Cancer?. European Urology, 2003, 44, 57-64.	0.9	45
20	Is Seminal Vesicle Ablation Mandatory for All Patients Undergoing Radical Prostatectomy?. European Urology, 2004, 46, 42-49.	0.9	45
21	The 20-Core Prostate Biopsy Protocol—A New Gold Standard?. Journal of Urology, 2008, 179, 504-507.	0.2	45
22	The use of estramustine phosphate in the modern management of advanced prostate cancer. BJU International, 2011, 108, 1782-1786.	1.3	37
23	Subcutaneous Pyelovesical Bypass As Replacement for Standard Percutaneous Nephrostomy for Palliative Urinary Diversion: Prospective Evaluation of Patient's Quality of Life. Journal of Endourology, 2007, 21, 173-176.	1.1	34
24	Are Repeat Biopsies Required in Men with PSA Levels ≥ 4 ng/ml? A Multiinstitutional Prospective European Study. European Urology, 2005, 47, 38-44.	0.9	32
25	Nephron-Sparing Surgery for Renal Tumors Measuring More Than 7 cm: Morbidity, and Functional and Oncological Outcomes. Clinical Genitourinary Cancer, 2014, 12, e19-e27.	0.9	31
26	The Learning Curve of Transrectal Ultrasound-guided Prostate Biopsies: Implications for Training Programs. Urology, 2013, 81, 12-16.	0.5	29
27	The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study. Urology, 2015, 86, 1185-1191.	0.5	27
28	Prostate Cancer Characteristics in a Multiracial Community. European Urology, 2008, 53, 533-539.	0.9	24
29	Clearance of Free and Total Serum PSA after Prostatic Surgery. European Urology, 1998, 33, 251-254.	0.9	19
30	Stage pT0 After Radical Prostatectomy With Previous Positive Biopsy Sets: A Multicenter Study. Journal of Urology, 2010, 183, 958-962.	0.2	16
31	Is there any evidence of superiority between retropubic, laparoscopic or robot-assisted radical prostatectomy?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2011, 37, 146-160.	0.7	16
32	T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept. Ecanermedicalscience, 2014, 8, 486.	0.6	16
33	Prostate Specimen Reevaluation in Patients With Organ Confined Prostate Cancer and Postoperative Biological Recurrence. Journal of Urology, 1996, 155, 1981-1982.	0.2	15
34	Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience. BMC Cancer, 2008, 8, 26.	1.1	14
35	^{18}F -Choline PET/CT and Prostate MRI for Staging Patients With Biochemical Relapse After Irradiation for Prostate Cancer. Clinical Nuclear Medicine, 2015, 40, e492-e495.	0.7	14
36	How to Preserve Continence after Radical Prostatectomy. European Urology Supplements, 2005, 4, 8-11.	0.1	13

#	ARTICLE	IF	CITATIONS
37	European Study of Radical Prostatectomy: time trends in Europe, 1993-2005. BJU International, 2007, 100, 22-25.	1.3	13
38	Sensitive Allele-Specific PCR Assay Able to Detect FGFR3 Mutations in Tumors and Urine from Patients with Urothelial Cell Carcinoma of the Bladder. Clinical Chemistry, 2005, 51, 1555-1557.	1.5	11
39	The Role of the Biopsy of the Transitional Zone and of the Seminal Vesicles in the Diagnosis and Staging of Prostate Cancer. European Urology Supplements, 2002, 1, 40-46.	0.1	10
40	PROSPECTIVE EVALUATION OF PROSTATE CANCER DETECTED ON BIOPSIES 1, 2, 3 AND 4. Journal of Urology, 2001, , 1679-1683.	0.2	10
41	Posterior urethral valves in adult with Down syndrome. Urology, 2006, 67, 424.e1-424.e2.	0.5	8
42	Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma. Molecular Carcinogenesis, 2010, 49, 25-31.	1.3	4
43	Chemotherapy of premalignant lesions: new insights. BJU International, 2007, 100, 18-21.	1.3	3
44	Towards Early and More Specific Diagnosis of Prostate Cancer? Identifying a Key Target Population for Chemoprevention and Available Strategies. European Urology Supplements, 2009, 8, 103-107.	0.1	3
45	Surgical Management of Kidney Cancer in France: Overview of the Last Decade. European Urology, 2012, 62, 942-943.	0.9	2
46	Diet and Chemoprevention of Prostate Cancer. European Urology Supplements, 2004, 3, 18-20.	0.1	1
47	Construction of a global score quantifying allelic imbalance among biallelic SIDP markers in bladder cancer. Statistics in Medicine, 2003, 22, 3771-3779.	0.8	0
48	Re: Transperineal Magnetic Resonance Image Targeted Prostate Biopsy Versus Transperineal Template Prostate Biopsy in the Detection of Clinically Significant Prostate Cancer. European Urology, 2013, 64, 337.	0.9	0